Our featured speaker for this post is Dr Alvin Luk, Senior Director, Global Clinical Affairs & Operations, Biogen Idec Hemophilia, United States. He will be presenting at Pharma Trials World Asia 2012, part of a series of conferences at the 5th Annual BioPharma Asia Convention 2012.
A brief introduction to begin with: Dr. Luk joined Biogen Idec's hemophilia therapeutic area in 2009, from Bayer Healthcare, Bayer Schering Pharma where he was Deputy Director, Global Clinical Program & Resource Management, with specific emphasis on hemophilia. He has more than 15 years of distinguished success in global clinical development and global clinical operations at a few firms including Avigen and Amgen (formerly Tularik). He is the co-author of 19 scientific papers, has 3 U.S. patents pending, a member of numerous medical and scientific groups including the WFH, NHF, ISTH, and ASH, and recipient of numerous special recognition awards. Dr. Luk received his B.S. in Biochemistry with a minor in Business Administration in Marketing and an M.S. in Cell Development & Physiology degrees, all from the University of California, Berkeley and a Ph.D. in Neuroscience from the University of California, San Francisco.
Dr Luk will be presenting on the following topics:
Planning your studies in South East Asia: Importance of understanding the local regulatory systems
1. Capitalizing on a thorough understanding of Southeast Asian countries to overcome barriers in clinical trials
2. Maximizing trial efficiency through careful planning and resource management
3. Case study: Tapping on Malaysia and Thailand's experienced healthcare workforce to conduct clinical trials
Dr Luk will also be speaking at the following panel:
Panel: Mapping out the challenges and opportunities for clinical trials in South East Asia
1. Optimizing your clinical trial strategies for the changing environment and challenges in South East Asia
2. Growing your clinical trials in South East Asia with opportunities to increase trial efficiency
3. Modifying your clinical trial plan with a thorough understanding of Asian regulatory systems to maximize clinical trial progress